Evaluating the Association between CCR5delta32 Polymorphism (rs333) and the Risk of Breast Cancer in a Cohort of Iranian Population

Background: cc chemokine receptor 5 (ccr5) is introduced as an immune response modulator. the activity of ccr5 influences breast tumour development in a p53-dependent manner. this study aimed to investigate the frequency of ccr5delta32 and its association with the risk of breast cancer in 1038 blood samples in north east of iran. methods: in this case-control study, we genotyped 570 control samples and 468 breast cancer patients by a gel electrophoresis-based gap-polymerase chain reaction (gap-pcr) method mashhad, iran. the data were analyzed using the spss software. results: of 570 controls included, 542 (95.09%) had ccr5delta32 wild/wild (w/w) genotype, 28 samples (4.91%) had ccr5delta32 wild/deletion (w/d) genotype and none of them were ccr5delta32 deletion/deletion (d/d) genotype (0%). while 428 samples of patients (91.45%) had ccr5delta32 w/w genotype, 40 samples (8.55%) had ccr5delta32 w/d and ccr5delta32 d/d homozygous was nil (0%) amongst cases. all samples were in the hardy–weinberg equilibrium (p>0.05). according to the allele frequency, d allele, as a risky allele, in the cases was more than the control samples (0.0427 vs 0.0245, respectively) (p=0.0206). hence, w/d genotype may confer a risk effect (or=1.77, ci: 1.09-2.90; p=0.0206) compared with ww genotype between case and control groups. conclusion: there is a statistically significant association between ccr5w/d and breast cancer risk. ccr5 may be regarded as a target for the prevention of breast cancer in certain conditions such as interaction with p53 variants, which remains to be further investigated.